Objective: To systematically review the literature for studies on cognitive functioning in patients with low-grade glioma to evaluate assessment methods and prevalence of cognitive dysfunction. Data sources: A search was made in PubMed, Embase, and PsycINFO for articles published between January 2002 and June 2012 using cognition, memory, attention, executive functioning, and low-grade glioma as search terms. Study selection: Two reviewers independently performed the study selection and data extraction. Inclusion criteria were: studies including at least 10 adult patients, with suspected or confirmed low-grade glioma and cognitive functioning as outcome measure. Data extraction: A standard data extraction form was used, with items regarding study quality, patient characteristics, type of measurement instruments, cognitive domain, definition of cognitive dysfunction, and reported prevalence. Data synthesis: Of the 312 articles screened on title/abstract, 69 were screened on full-text and, finally, 17 were included. A total of 46 different measurement instruments were found for the assessment of cognitive functioning; 5 of these were used 5 or more times. There was variability in the definition of cognitive dysfunction. The reported prevalence of cognitive dysfunction ranged from 19% to 83%. Conclusion: Many patients with low-grade glioma experience cognitive dysfunction. However, there is no consensus on how to assess cognitive functioning in these patients.
INTRODUCTION
Lowgrade gliomas (LGGs) are primary brain tumours arising from glial cells, the supporting cells of the central nervous system (CNS). Lowgrade gliomas can include astrocytomas, oligodendrogliomas, ependymomas or mixed gliomas (e.g. oli goastrocytomas). According to the World Health Organization (WHO) LGGs can be classified as grade I or grade II, based on the presence of histopathological features (e.g. atypical cells, mitoses, endothelial proliferation, and necrosis) (1) .
Only 15-20% of all gliomas are considered to be lowgrade ones (2, 3) . The mean incidence in Europe of LGG is approxi mately 1/100,000 persons/year (2, 3). The peak incidence is in young adults, aged approximately 30-40 years (4, 5) . The survival rate of patients with LGG is increasing due to im proved neurosurgical techniques, advanced radiotherapy and chemotherapy, with median survival times ranging from 5 to 15 years (6, 7). There is still controversy with respect to the best timing of treatment, in particular surgery and radiotherapy. As such, therapy choices may vary across clinicians or hospitals, while patients with LGGs may face longterm consequences in which cognitive, emotional, linguistic and sensorimotor dysfunction may interfere with daily activities and social participation (8) (9) (10) .
Besides surgery, chemotherapy, radiotherapy and psycho social support, some patients might benefit from cognitive rehabilitation. There is a growing awareness that these patients might also benefit from multidisciplinary rehabilitation pro grammes. Multidisciplinary rehabilitation programmes may improve functional outcome, mood, vocation and quality of life in patients with a brain tumour (9, (11) (12) (13) (14) . However, subacute rehabilitation in patients with LGG is not common practice and has not been well studied. There is still a large gap between current research in the area of the functional consequences of LGG and its actual treatment in multidisciplinary rehabilita tion programmes (15) .
Cognitive functioning is pivotal for social participation and quality of life (16) . In patients with LGG, cognitive function ing may vary over time and is influenced by a combination of tumour characteristics (location, type, and size of tumour), treatment modalities (surgery, radiation therapy, chemo therapy), comorbidity (epilepsy, use of anticonvulsants) and contextual factors such as educational level and coping style (17, 18) . A decline in functioning will occur due to the pro gressive nature of the condition. Such a decline may support clinical decisionmaking (for example, to decide on planning surgical intervention and/or radiotherapy) or it may cause unresponsiveness to rehabilitation.
Cognitive deficits in patients with a brain tumour can affect attention, memory and executive functioning (19, 20) with a reported prevalence of 29-90% (9, (20) (21) (22) . Besides variability in the type of tumour, the use of various neuropsychological instruments, different cutoff scores and normative data may explain this wide range (23) . Knowledge about cognitive deficits is important as they provide insight into prognosis and followup of the disease, and can be used to evaluate treatment (side) effects and to target cognitive rehabilitation (24) .
Therefore, this systematic review focuses on how to measure cognitive functioning in patients with LGG. These patients are relatively young and, with a life expectancy of 5-15 years, and might benefit from multidisciplinary (cognitive) rehabilitation programmes. We focus on the 3 pillars of cognitive function ing: memory, attention and executive functioning. The primary aim of this study is to systematically review the literature on how memory, attention and executive functioning are assessed in patients with LGG. The secondary aim is to compare the reported prevalence of cognitive dysfunction in patient popu lations with LGG.
METHODS

Data sources
A search was performed in PubMed, PsychINFO and Embase for articles published between January 2002 and June 2012. In addition, the reference lists of all identified publications were checked. The search strategy was developed and tested for PubMed and adapted for PsychINFO and Embase. The following search terms were used: lowgrade glioma, cognition, memory, attention, and executive func tioning (Table I) .
Study selection
Studies were included if all of the following criteria were met: (i) the study population included patients with suspected or confirmed LGG; (ii) the results of these patients were distinguishable from any other patient group; (iii) the study population consisted of ≥ 10 patients; (iv) patients were at least 16 years of age at the time of diagnosis; and (v) cognitive functioning was 1 of the outcome measures.
Articles were excluded if: (i) the study design was a review or case study; (ii) no full text was available; (iii) written in a language other than English, Dutch, German or French; (iv) reported only duplicate data; or (v) assessed language capabilities only (i.e. aphasia examina tions). Tests of verbal fluency were not considered to be instruments used only for assessing language capabilities, as these can also serve as suitable measures of executive functioning (25) .
Two authors (EvL, WvL) independently performed selection of the studies. The first selection was based on title and abstract, and relevant articles were retrieved in full text. Fulltext papers were also retrieved if abstracts were missing or if they provided insufficient information to enable selection. The final selection was based on scrutinizing the fulltext articles. In case of disagreement between the reviewers, consensus was sought. If the disagreement was not resolved, a third reviewer (GR) made the final decision. The reference lists of the selected articles were reviewed by the first author to identify additional articles.
Data extraction
Two authors independently extracted data from the selected articles us ing a standard data extraction form. Data included items of study qual ity (study design, selection of study population, definition of disease, description of treatment, followup time, numbers lost to followup), population characteristics (number of patients, diagnosis, mean age, male/female ratio, mean time postdiagnosis), and items of cognitive assessment. Items of cognitive assessment included: (i) the cognitive domains tested: attention, memory, executive functioning and/or other cognitive domains (e.g. visioconstruction) were primarily based on Lezak (25) ; (ii) the definition of cognitive dysfunction; (iii) cognitive tests used; and (iv) the reported prevalence of cognitive dysfunction in the study population. Brief cognitive screening instruments, such as the MiniMental State Examination (MMSE), were grouped under "other" cognitive domains since these instruments provide only a brief and basic assessment of multiple cognitive domains. In cases of missing data the corresponding authors were contacted by email.
Data synthesis
The focus of this systematic review was to study the instruments used for the cognitive assessment of patients with LGG, and the reported prevalence of cognitive dysfunction. Therefore, the qualitative results of this review are presented in tables using descriptive statistics to characterize the study populations. The measurement instruments used for the assessment of cognitive functioning were studied in detail and briefly described based on the existing literature, particularly Neuropsychological Assessment by Lezak (25) , which is a standard in this field (26, 27) . Because neuropsychological tests are often described using different names, to avoid confusion the name of the instrument as described by Lezak (25) was used, if available.
RESULTS
The initial literature search yielded 515 articles. After exclu sion of duplicate articles, 312 articles were included in the first screening phase (title/abstract), resulting in 69 articles eligible for the second screening phase. After review of the full text, 22 potentially eligible articles remained. After a third round of critical fulltext analysis, 4 articles (28-31) were excluded because the data overlapped with previous reports, and 1 article (32) was excluded because it reported only on tests assessing language capabilities. Finally, 17 articles were included in the present review ( Fig. 1 . shows the selection procedure). Embase ((Glioma/exp OR astrocytoma/exp OR glioma*:ab,ti OR astrocytoma*:ab,ti OR ependymoma*:ab,ti OR oligodendroma*:ab,ti) AND ('low grade':ab,ti OR 'grade I':ab,ti OR 'grade II':ab,ti OR 'grade 1':ab,ti OR 'grade 2':ab,ti OR 'grade1':ab,ti OR 'grade2':ab,ti)) AND (cognitive:ab,ti OR cognition:ab,ti OR cogniti*:ab,ti OR memory:ab,ti OR memor*:ab,ti OR attention:ab,ti OR executive:ab,ti) psycINFO (OR) glioma* astrocytoma* ependymoma* oligodendroma* (AND) (low grade) (AND) (OR) cognitive cognition cogniti* memory memor* attention executive
Study population
Of the 17 articles, those of MoritzGasser et al. (33) and Shankar & Rajshekhar (34) both reported results of a retro spective and a prospective study population in 1 publication; therefore, we decided to split both articles into 2 separate studies, resulting in a total of 19 studies.
The articles of Klein et al. (35) and the followup study of Douw et al. (7) have overlapping (sub)populations, and the study population of Laack et al. (36) consists of a subpopulation of the study of Brown (37) . Finally, all 19 study populations were included in our analyses, because all underwent different cognitive tests and/or outcome measurements.
In this review, the total study population consisted of 775 patients with LGG. In 513 patients a complete description of the type of LGG was provided: the most common diagnosis was astrocytoma (61.0%), followed by oligodendroglioma (24.6%) and oligoastrocytoma (13.3%). The mean age of the total population (average of reported means) was 42.3 (range 38.1-46.7) years and the reported time postdiagnosis ranged from 1 month to 32 years (mean 63 months).
Of the 17 studies, 13 (representing 566 patients) featured cognition as a primary outcome measure. Most studies evalu ated (only) the effect of a specific form of treatment: radio therapy in 7 studies (n = 260), awake surgery in 4 (n = 49), and a combination of chemotherapy and awake surgery in 1 (n = 10). Seven studies (n = 180) were performed before start ing any treatment.
Eight studies (n = 318) had a prepost study design and 11 (n = 457) had a crosssectional study design. The followup period ranged from 3 to 40 months. Table II presents an overview of the studies and the baseline characteristics of the patient populations.
Measurement instruments
We identified 46 different instruments used for the assessment of cognitive functioning (Table III) Table III because the exact nature of these tests could not be established. Most of the tests were domain-specific. The MMSE and the Functional Assessment Measure provide a global (screening) measure of cognitive function.
Cognitive assessment
Memory was assessed in 13 studies, attention in 12, and execu tive functioning in 11.
In 11 studies all 3 domains were measured, of which 6 studies also included other domains, such as information processing and language. One study focused only on the memory domain. In 4 studies only a global cognitive screening test was used, the MMSE in 3 studies and the Functional Assessment Measure in 1 study. Table IV presents an overview of the study outcomes.
The definition of cognitive dysfunction varied considerably between articles. Seven studies defined cognitive dysfunction as a number of standard deviations (SD) below the mean of a normative sample, represented in terms of Zscores (4, 7, 33, 35, (38) (39) (40) . The cutoff points ranged from 1-2 SD below the mean of a normative sample, with 2 SD being the most common cut-off point. Five studies reported other definitions of cogni tive dysfunction. Brown (37) defined cognitive dysfunction using a test-specific cut-off score ≤ 26 on the MMSE. The prevalence of cognitive dysfunction could be deducted from 8 of the 17 articles (47%) and ranged from 19% to 83%.
DISCUSSION
The primary aim of this study was to systematically review the literature for assessment methods used for cognitive func tioning in patients with LGG. Our search focused on memory, attention and executive functioning, i.e. the 3 main pillars of cognition (25) .
In the 17 reviewed articles, 775 patients with LGG were as sessed using 46 different instruments. Only 5 instruments were used 5 times or more, i.e. the MMSE, Stroop Test, Trail Mak ing Test and tests of phonemic and semantic verbal fluency. In (52) 19 (44) 14 (33) 5 (12) . 
Bells Test Circle 35 bells scattered amongst 315 objects pseudorandomly distributed on a page, as quickly as possible.
Benton Visual Retention Test
Recall a 3-figure design by drawing.
Block Design Use blocks to construct replicas of model designs. Brixton Spatial Anticipation Test Predict the location of a coloured circle among white circles, determined by 1 of 9 rules based on its position on preceding cards.
Concept Shifting Test Cross out numbers consecutively, letters alphabetically, alternating numbers and letters, and empty circles in a clockwise fashion (53) . (6, 7, 35) Cube Analysis Count the total number of blocks in 3dimensional piles, presented in 2dimensional drawings. 
Grooved Pegboard Insert pegs that have a ridge along 1 side in a board with a 5×5 set of slotted holes by rotation of the pegs.
Hopkins Verbal Learning Test 20-25 min delayed recall trial of a 12word list, followed by a recognition trial with distractions. Letter Digit Substitution Test Letters are paired with randomly assigned digits from 1 to 9. Match the letters with digits according to a key (56) . (6, 7, 35) LetterNumber Sequencing Alternating numbers and letters are read aloud. Subjects need to repeat the numbers first, followed by the letters, both in ascending order.
(33, 38)
Line Bisection Test Subjects have to "cut" line segments of various sizes in half by placing a pencil mark.
Matrix Reasoning Incomplete matrices need to be completed, choosing the item that best completes the pattern(s) from a multiplechoice array.
MiniMental State Examination Screening test of cognitive functions: orientation for time and place, memory, attention, and language (55).
(2, 4, 36-38, 52)
Müncher Verbaler Gedachtnistest German version of the California Verbal Learning Test. 15word lists are used to assess immediate and delayed recall with distraction (57).
Picture Arrangement Subjects have to arrange sets of cartoon pictures in such an order that they represent the most sensible story.
Position Discrimination Two identical squares with a black dot are presented: 1 in the centre, 1 offcentred. Pick the square that contains the centred dot.
Post Graduate Institute Scale of Memory Memory assessment battery standardized for the Indian population (58). Test consists of a complex figure that the subjects need to copy, recall immediately, after a delay, or a combination of the 3.
(38-40)
Selective Reminding Subjects hear a list of words for immediate recall, repeatedly followed by a list of omitted words until all words are recalled.
Similarities Subjects are presented with pairs of concepts and have to explain what each pair has in common.
Stroop Test Subjects are presented with colour words printed in a different colour ink and have to name the colour of the ink rather than reading the words. (4, 6, 7, 35, 36, 38) Symbol Digit Modalities Test Digits paired with a randomly assigned symbol are presented. Fill in the blanks with numbers according to a key. 
Trail Making Test Subjects draw lines to connect consecutively numbered circles (part A) and to connect alternating numbers and letters (part B). (4, 33, 36, 38, 40) Verbal Fluency, phonemic Subjects need to say as many words as they can that begin with a given letter of the alphabet, during a certain amount of time. (4, 5, 33, 36, (38) (39) (40) (41) Verbal Fluency, semantic Subjects need to say as many words as they can that belong to a given semantic category (e.g. "animals"), during a certain amount of time.
(4-7, 33, 35, 38)
Visual Memory Span Subjects are asked to reproduce spatial patterns on an array of blocks, either forwards or backwards.
Visual Verbal Learning Test 15 common monosyllabic nouns are used to assess free recall, repeatedly followed by a list of mistakes, delayed recall, and recognition. (6, 7, 35) Vocabulary Subjects are presented with 30 words, 1 at a time and in order of difficulty, of which they have to explain the meaning.
Wechsler Adult Intelligence Scale (WAIS) Test consists of a test battery for measuring intelligence.
Wisconsin Card Sorting Test Work out the correct principle by which to sort the cards from the examiner's "right" or "wrong" responses to the placement of the cards.
a Primarily based on Lezak (25) , if additional references are used these are mentioned; b articles that used this specific measurement instrument.
these latter studies, the main reason for cognitive testing was to evaluate the effects of treatment. The fact that 46 different instruments were found indicates that no single standard test battery is used for the assessment of cognitive function in patients with LGG. Wilde et al. (43) recommended that cognitive tests should meet the following 7 criteria: widespread use, adequate psychometric properties, availability of norms, applicability across a range of injury severity and functional levels, accessible through the public domain, ease of administration, and brevity. An additional fea ture of the test should be its sensitivity to even small changes in cognitive functioning in patients with LGG.
To create more uniformity in studies on patients with LGG, Correa et al. (44) However, none of the articles in this current review included all of these tests. This battery is currently widely used in prospective randomized multicentre phase III trials, for both high and lowgrade gliomas.
As an alternative to formal testing, the use of patientreported outcome measures (PROMs) with selfreport questionnaires on cognitive complaints is suggested. Selfreported outcomes of the patients and their caregivers may provide useful additional information. The European Organization for Research and Treat ment of Cancer brain cancer qualityoflife module (EORTC QLQBN20) (47) and the Cognitive Functional Scale, developed for use in the Medical Outcomes Study (MOSCFS) (48) , are examples of such PROMs. Aaronson et al. (49) used the MOS CFS and concluded that 25% of the patients with LGG had fre quent problems with memory and concentration. Complaints of being confused, having problems maintaining attention, having difficulty with solving problems, or having slowed reactions, were reported in 10-18% of patients with LGG.
Our second aim was to compare the reported prevalence of cognitive dysfunction in patients with LGG. The prevalence of cognitive dysfunction in the included articles ranged from 19% to 83%. This wide range may depend on the characteristics of the glioma (type, location, and size), the type of treatment, the time of measurement, the neuropsychological tests used, and the definition of cognitive dysfunction, all of which varied substantially between studies. This heterogeneity makes it difficult to draw general conclusions about the prevalence of cognitive dysfunction in patients with LGG.
Every effort should be made to reliably assess cognitive function in patients with LGG as this may support clinical decisionmaking; for example, to decide on planning surgical intervention or for targeting rehabilitation programmes.
Unfortunately, most studies included in this review had no (or only a very short) followup period.
Finally, it should be noted that this review focused on memory, attention and executive functioning. Cognitive do mains, such as language, visuoconstruction and perception, fell outside the scope of this research. This could be a limitation of this review, resulting in an underestimation of the cognitive disorders of patients with LGG as well as the variety of instru ments used to measure these disorders. In a retrospective study, Lageman et al. (50) concluded that in clinical trials, visuo construction, processing speed and verbal memory may be the most important domains to assess when evaluating cognitive deficits in patients with a primary brain tumour.
In conclusion, patients with LGG are often young and may have a life expectancy of 5-15 years, in which they may experience cognitive dysfunction and complaints that might benefit from multidisciplinary rehabilitation programmes. The present systematic review has shown that a wide range of neu ropsychological tests are used, together with various criteria, to define cognitive dysfunction. Future studies should focus on the reliable assessment of cognitive function in patients with LGG in order to support clinical decisionmaking, and improve the targeting of rehabilitation programmes.
